Versacloz is owned by Tasman Pharma.
Versacloz contains Clozapine.
Versacloz has a total of 1 drug patent out of which 0 drug patents have expired.
Versacloz was authorised for market use on 06 February, 2013.
Versacloz is available in suspension;oral dosage forms.
The generics of Versacloz are possible to be released after 01 May, 2028.
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8057811 | TASMAN PHARMA | Stable clozapine suspension formulation |
May, 2028
(4 years from now) |
Drugs and Companies using CLOZAPINE ingredient
Market Authorisation Date: 06 February, 2013
Treatment: NA
Dosage: SUSPENSION;ORAL
2
New Zealand
2
United States
1
Spain
1
Canada
1
Australia
1
European Union
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic